menu
    • menu
    [{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"SION-638","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SION-638","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SION-109","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"SION-638","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Enavate Sciences"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Sionna Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Sionna Therapeutics \/ Sionna Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Sionna Therapeutics

    Menu

    Sionna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galicaftor,Navocaftor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sionna Expands CF Pipeline with AbbVie License Agreement

                            Details : Under the terms of the agreement, Sionna will assume all development for ABBV-2222 (galicaftor), which is being evaluated in combination with navocaftor for the treatment of Cystic Fibrosis.

                            Brand Name : ABBV-2222

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Galicaftor,Navocaftor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SION-638

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Enavate Sciences

                            Deal Size : $182.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Sionna Therapeutics Announces $182M Series C for Novel Cystic Fibrosis Molecules

                            Details : Proceeds will support clinical development of SION-638, a first-in-class small molecule designed to restore CFTR protein function by stabilizing the first nucleotide-binding domain.

                            Brand Name : SION-638

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 06, 2024

                            Lead Product(s) : SION-638

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Enavate Sciences

                            Deal Size : $182.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SION-109

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis

                            Details : SION-109 targets the interface between the ICL4 region and NBD1 of the CFTR protein, and is in phase 1 development for treating delta-F508 mutated Cystic Fibrosis.

                            Brand Name : SION-109

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2024

                            Lead Product(s) : SION-109

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SION-638

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis

                            Details : SION-638, a novel small molecule designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

                            Brand Name : SION-638

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : SION-638

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Sionna Therapeutics

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SION-638,Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : OrbiMed

                            Deal Size : $111.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules...

                            Details : Sionna is advancing a pipeline of first-in-class small molecules, SION-638, designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in CF, by stabilizing CFTR's first nucleotide-b...

                            Brand Name : SION-638

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 19, 2022

                            Lead Product(s) : SION-638,Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : OrbiMed

                            Deal Size : $111.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth